Investors holding their breath for the approval of GlaxoSmithKline
The final two trials in COPD, pitting Relovair directly against Advair, weren't required to get Relovair on the market, but they will help sell the product. In one trial, Relovair was superior to Advair. In another the data was trending that way, but the improvement wasn't statistically significant. If the trials were required for approval, I'd be worried about the miss on the second trial, but since they're just to support marketing, the data seem solid enough.
On the asthma side, a trial comparing one of the active ingredients in Relovair, fluticasone furoate, to the similar compound in Advair, fluticasone propionate, showed they were both better than placebo in treating asthma patients. Glaxo didn't release the full data, but based on the P values, we can guess that the Relovair component was slightly better than the Advair component.
Converting patients from Advair, an $8.1 billion drug, to Relovair is important because of the possibility that Advair might face generic competition at some point. Relovair only has to be taken once a day, which is more convenient than the twice-daily Advair formulation. And the trial showing that Relovair is superior to Advair will help, although two statistically significant trials would obviously be better.
But Glaxo's best weapon for converting patients from Advair to Relovair might be that it owns Advair. Increasing the price of Advair will push insurers to encourage their members to switch to the lower-cost treatment. Glaxo just needs to be careful not to push patients off Advair and onto the competition: Merck's
The son of Advair has been a long time coming -- the deal between Glaxo and Theravance dates back to 2002 -- but it looks like investors can breathe easy until next year, when competition heats up in the COPD market.
Breathe even easier with these three stocks that will help you retire rich.
Fool contributor Brian Orelli holds no position in any company mentioned. Click here to see his holdings and a short bio. Motley Fool newsletter services have recommended buying shares of Pfizer and GlaxoSmithKline. The Motley Fool has a disclosure policy.
More from The Motley Fool
3 Top Dividend Stocks With Yields Over 4%
High-yield stocks have gotten harder to find in the current bull market, but these three should please even the pickiest income investors.
3 High-Yield Stocks Still Worth Buying
All three companies pay at least double the average yield of the S&P 500.
Is a Dividend Cut Coming From GlaxoSmithKline plc?
Is the company's rich yield an opportunity for investors, or a warning of trouble ahead?